Sylvie Jorieux
8Patents
4h-index
12Co-inventors
50Inventor score
Filing activity: Jul 30, 2004 → Jan 12, 2016
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7713524B2 | Use of ADCC-optimized antibodies for treating low-responder patients | Emerging Cross-Sectional Technologies | 26 | Expired |
| US8742074B2 | Optimized FC variants | Chemistry; Metallurgy | 12 | Active |
| USRE45992E1 | Optimized FC variants | General | 12 | Active |
| US8501171B2 | Use of ADCC-optimized antibodies for treating weak patients | Emerging Cross-Sectional Technologies | 6 | Active |
| USRE46585E1 | Optimized FC variants | General | 1 | Active |
| US9879089B2 | Use of ADCC-optimized antibodies for treating low-responder patients | Emerging Cross-Sectional Technologies | 0 | Active |
| US8404241B2 | Anti-rhesus D monoclonal antibody | Chemistry; Metallurgy | 0 | Active |
| US9109020B2 | Use of ADCC-optimized antibodies for treating weak patients | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.